Biomea Fusion Inc (NAS:BMEA)
$ 4.39 0.16 (3.78%) Market Cap: 157.80 Mil Enterprise Value: 18.22 Mil PE Ratio: 0 PB Ratio: 1.16 GF Score: 40/100

Biomea Fusion Inc to Discuss FDA Clearance of IND for BMF-219 in Type 2 Diabetes Transcript

Dec 15, 2022 / 09:00PM GMT
Release Date Price: $7.47 (+2.05%)
Operator

Good day and thank you for standing by. Welcome to the FDA clearance of IND for BMF-219 in type 2 diabetes conference call.

At this time, all participants are on a listen-only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Ramses Erdtmann, President of Biomea Fusion. Please go ahead.

Ramses Erdtmann
Biomea Fusion, Inc. - COO, President and Co-Founder

Thank you, operator. Good afternoon, everyone, and thank you for dialing in. My name is Ramses Erdtmann. I'm the COO, President and Co-Founder of Biomea. With me on the call today from our team and available to answer questions are our CEO and Chairman, Tom Butler, also Co-Founder of Biomea, as well as our CMO, Dr. Steve Morris, our Senior Medical Director, Dr. Sanchita Mourya, and our Associate Director of Translational Research, Dr. Priyanka

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot